Baicalin attenuates malignant progression of salivary adenoid cystic carcinoma by downregulating the STIM1-SOCE/c-Myc/RPL35-mediated ribosomal pathway via ubiquitination
Journal of Natural Medicines · 30.10.2026
DOI: 10.1007/s11418-026-02099-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Natural Medicines, online erschienen am 30.10.2026. Verfasst von Tangjun Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Stomatology, Shandong Second Medical University, Weifang, China. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This study aimed to define the STIM1-SOCE/c-Myc/RPL35 axis driving malignant progression and cisplatin resistance in salivary adenoid cystic carcinoma (SACC), and elaborate the anti-SACC mechanisms of baicalin (BA). Transcriptomics was performed on STIM1-overexpressing (STIM1-OE) and control SACC-83 cells. A panel of cellular functional tests, western blotting, molecular docking, xenograft models and cell co-culture assays were applied to validate pathway function as well as BA’s pharmacological and immunomodulatory effects. Transcriptomic data revealed that STIM1 activated ribosomal signaling by boosting SOCE activity, upregulating c-Myc and its downstream RPL35, whereas STIM1 overexpression conferred cisplatin resistance to SACC cells. Molecular docking verified favorable binding affinity between BA and STIM1/c-Myc/RPL35. BA concentration-dependently suppressed SACC proliferation, migration, invasion and angiogenesis, with stronger efficacy in STIM1-OE cells. Mechanistically, BA triggered ubiquitin-proteasome-dependent degradation of these three proteins, which was rescued by MG132; BA also suppressed SOCE to abrogate oncogenic ribosomal signaling. Besides, BA downregulated PD-L1 and reversed STIM1-induced M2 macrophage polarization to restore anti-tumor immunity, while in vivo xenograft assays validated BA’s inhibitory effects on tumor growth and angiogenesis. In summary, the STIM1-SOCE/c-Myc/RPL35 cascade promotes SACC progression and platinum resistance. BA exerts potent anti-SACC effects by degrading core pathway molecules and remodeling the tumor immune microenvironment, indicating BA as a low-toxic candidate therapy for STIM1-high SACC. Graphical abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Stomatology, Shandong Second Medical University, Weifang, China.
- Key Laboratory of Molecular Pharmacology and Translational Medicine, Department of Pharmacology, School of Pharmacy, Shandong Second Medical University, Weifang, China. 18765109573@sdsmu.edu.cn.
- Department of Clinical Pharmacy, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
- Key Laboratory of Molecular Pharmacology and Translational Medicine, Department of Pharmacology, School of Pharmacy, Shandong Second Medical University, Weifang, China.
- School of Stomatology, Shandong Second Medical University, Weifang, China. yunxialiu@sdsmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, T., Sun, Z., Xu, H., Liu, J., Cheng, X., Yue, H., Li, K., & Liu, Y. (2026). Baicalin attenuates malignant progression of salivary adenoid cystic carcinoma by downregulating the STIM1-SOCE/c-Myc/RPL35-mediated ribosomal pathway via ubiquitination. Journal of Natural Medicines. https://doi.org/10.1007/s11418-026-02099-2
Vancouver
Liu T, Sun Z, Xu H, Liu J, Cheng X, Yue H, et al. Baicalin attenuates malignant progression of salivary adenoid cystic carcinoma by downregulating the STIM1-SOCE/c-Myc/RPL35-mediated ribosomal pathway via ubiquitination. Journal of Natural Medicines. 2026. doi:10.1007/s11418-026-02099-2
BibTeX
@article{Liu2026,
author = {Liu, Tangjun and Sun, Zhipeng and Xu, Huanhuan and Liu, Jialu and Cheng, Xiaoting and Yue, Hongye and Li, Kaiwen and Liu, Yunxia},
title = {Baicalin attenuates malignant progression of salivary adenoid cystic carcinoma by downregulating the STIM1-SOCE/c-Myc/RPL35-mediated ribosomal pathway via ubiquitination},
journal = {Journal of Natural Medicines},
year = {2026},
doi = {10.1007/s11418-026-02099-2}
}
EUVIMED